Development and Testing of Adolescent Twelve-Step Facilitation

Sponsor
Massachusetts General Hospital (Other)
Overall Status
Completed
CT.gov ID
NCT01449981
Collaborator
(none)
59
1
2
51
1.2

Study Details

Study Description

Brief Summary

This study is the first to develop and test in a randomized experimental design the efficacy of an integrated 12-step facilitation intervention tailored for young people. In the first phase of the study, the investigators are developing and revising a preliminary manual for the two sessions individually-delivered Motivational Enhancement Therapy (MET) component and subsequent 8 session group-delivered Cognitive-Behavioral Therapy (CBT) component which will integrate Twelve-step Facilitation (TSF). Forty adolescents each will complete the preliminary integrated TSF protocol. In the second phase of the study, the investigators will compare integrated TSF (iTSF) to standard treatment (MET/CBT) in a randomized experimental design for adolescent substance use disorder with 60 adolescents. As a result, the investigators will examine potential mechanisms that may underlie the efficacy of iTSF in improving alcohol and other drug use outcomes. The investigators will test group differences on potential mechanisms of change (e.g., Alcoholics Anonymous/Narcotics Anonymous attendance and involvement) and whether these variables are associated with substance use outcomes.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Integrated Twelve-Step Facilitation
  • Behavioral: Cognitive Behavioral Therapy
N/A

Study Design

Study Type:
Interventional
Actual Enrollment :
59 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Development and Testing of Adolescent Twelve-Step Facilitation
Study Start Date :
Oct 1, 2011
Actual Primary Completion Date :
Mar 1, 2015
Actual Study Completion Date :
Jan 1, 2016

Arms and Interventions

Arm Intervention/Treatment
Experimental: Integrated Twelve-Step Facilitation

Behavioral: Integrated Twelve-Step Facilitation
The iTSF condition will include review of treatment goals and overall review of progress, coping skills, real life practices, emotions/mood management, how to make changes in one's social network and discussions about how 12-step meetings can be helpful in one's recovery efforts. In addition, speakers from 12-step fellowships such as Alcoholics Anonymous (AA) and Narcotics Anonymous (NA) will be invited to share their experiences and discuss myths and facts related to attendance at 12-step meetings as well as answer any questions participants have about these fellowships.
Other Names:
  • iTSF
  • Experimental: Cognitive Behavioral Therapy

    Behavioral: Cognitive Behavioral Therapy
    The CBT condition will include review of progress, coping skills, group exercises, real life practice, and emotions/mood management.
    Other Names:
  • CBT
  • Outcome Measures

    Primary Outcome Measures

    1. Percent Days Abstinent (PDA) [Up to 9 months]

      Given the goals of both treatments will be abstinence, the main outcome analyses and effect size estimates will be based upon biochemically verified 90 day point-prevalence of PDA. These will be captured using Form-90 (Miller & Del Boca, 1994) which will be used to examine substance use (including number of days used and first and last dates of use within the time period), as well as other treatment experiences in the past 90 days.

    Secondary Outcome Measures

    1. Treatment Acceptability [Up to 3 months]

      Participants will also complete weekly treatment feedback measures to inform the treatment manual.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    14 Years to 21 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Young people between the ages of 14 and 21 that meet criteria for alcohol or other drug abuse or dependence.

    Exclusion Criteria: Youth

    • with an active psychotic disorders

    • who are in another substance use disorder (SUD) treatment program or receiving SUD related psychotherapy that could conflict with our treatment

    • with a history of severe or complicated withdrawal (e.g., alcohol seizure history)

    • who may be using alcohol/drugs prior to study entry at levels likely to result in severe withdrawal complications, in the absence of any history

    • taking addiction treatment medications (e.g., Buprenorphine)

    • who cannot speak English because the treatment and assessment instruments will be conducted in English

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Center for Addiction Medicine 60 Staniford Street Boston Massachusetts United States 02114

    Sponsors and Collaborators

    • Massachusetts General Hospital

    Investigators

    • Principal Investigator: John F. Kelly, Ph.D., Massachusetts General Hospital

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    John F. Kelly, Associate Director MGH Center for Addiction Medicine, Massachusetts General Hospital
    ClinicalTrials.gov Identifier:
    NCT01449981
    Other Study ID Numbers:
    • NIAAA R01AA019664
    First Posted:
    Oct 10, 2011
    Last Update Posted:
    Sep 13, 2016
    Last Verified:
    Sep 1, 2016
    Keywords provided by John F. Kelly, Associate Director MGH Center for Addiction Medicine, Massachusetts General Hospital
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Sep 13, 2016